Analysis of the effectiveness rate of rapid serological tests for COVID-19 registered in ANVISA, a systematic review in the literature
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , |
| Tipo de documento: | Artigo |
| Idioma: | por |
| Título da fonte: | Research, Society and Development |
| Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/19615 |
Resumo: | Introduction: The immunological tests for COVID-19 have the great advantage of their diagnostic speed, but their efficiency rate varies depending on the manufacturer, generating the need to identify the best tests to be used in order to avoid false diagnoses. Objective: To point out the tests available in Brazil, which within the clinical trials sought, have a better rate of effectiveness. Methods: Articles referring to clinical trials that test the effectiveness of rapid tests for the detection of anti-SARS-COV-2 immunoglobulins were searched in the literature. For this purpose, a systematic search was carried out in the SCIELO, LILACS, PUBMED and MEDLINE databases using the descriptors SARS-COV-2, ELISA, COVID-19 and Assessment in association using the Boolean operator AND, followed by the application of criteria for inclusion and exclusion to select the papers to be included in the review. Results: 16 articles that tested 18 of the rapid tests available in the country were included. Conclusion: serological tests are a valuable tool to fight the SARS-COV-2 pandemic, but should not be used as a single tool in the diagnosis of viral infection given the period of immunological window. The ideal use of the tests will occur in cases where the patient already has more than 14 days of symptoms. The One Step COVID-2019 test from Guangzhou Wondfo Biotech revealed the best performance among those analyzed. |
| id |
UNIFEI_ea141f5cbc82164a8b52889b02672220 |
|---|---|
| oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/19615 |
| network_acronym_str |
UNIFEI |
| network_name_str |
Research, Society and Development |
| repository_id_str |
|
| spelling |
Analysis of the effectiveness rate of rapid serological tests for COVID-19 registered in ANVISA, a systematic review in the literatureAnálisis de la tasa de efectividad de las pruebas serológicas rápidas para COVID-19 registradas en ANVISA, una revisión sistemática de la literaturaAnálise da taxa de eficácia dos testes sorológicos rápidos para COVID-19 registrados na ANVISA, uma revisão sistemática na literaturaSARS-COV-2ELISACOVID-19Avaliação.SARS-COV-2ELISACOVID-19Evaluación.SARS-COV-2ELISACOVID-19Evaluation.Introduction: The immunological tests for COVID-19 have the great advantage of their diagnostic speed, but their efficiency rate varies depending on the manufacturer, generating the need to identify the best tests to be used in order to avoid false diagnoses. Objective: To point out the tests available in Brazil, which within the clinical trials sought, have a better rate of effectiveness. Methods: Articles referring to clinical trials that test the effectiveness of rapid tests for the detection of anti-SARS-COV-2 immunoglobulins were searched in the literature. For this purpose, a systematic search was carried out in the SCIELO, LILACS, PUBMED and MEDLINE databases using the descriptors SARS-COV-2, ELISA, COVID-19 and Assessment in association using the Boolean operator AND, followed by the application of criteria for inclusion and exclusion to select the papers to be included in the review. Results: 16 articles that tested 18 of the rapid tests available in the country were included. Conclusion: serological tests are a valuable tool to fight the SARS-COV-2 pandemic, but should not be used as a single tool in the diagnosis of viral infection given the period of immunological window. The ideal use of the tests will occur in cases where the patient already has more than 14 days of symptoms. The One Step COVID-2019 test from Guangzhou Wondfo Biotech revealed the best performance among those analyzed.Introducción: Las pruebas inmunológicas para COVID-19 tienen la gran ventaja de su rapidez diagnóstica, pero su tasa de eficiencia varía según el fabricante, generando la necesidad de identificar las mejores pruebas a utilizar para evitar falsos diagnósticos. Objetivo: Señalar las pruebas disponibles en Brasil, que dentro de los ensayos clínicos buscados, tienen una mejor tasa de efectividad. Métodos: Se buscaron en la literatura artículos referentes a ensayos clínicos que prueban la efectividad de las pruebas rápidas para la detección de inmunoglobulinas anti-SARS-COV-2. Para ello, se realizó una búsqueda sistemática en las bases de datos SCIELO, LILACS, PUBMED y MEDLINE utilizando los descriptores SARS-COV-2, ELISA, COVID-19 y Assessment en asociación utilizando el operador booleano AND, seguido de la aplicación de criterios. para su inclusión y exclusión para seleccionar los artículos que se incluirán en la revisión. Resultados: Se incluyeron 16 artículos que probaron 18 de las pruebas rápidas disponibles en el país. Conclusión: las pruebas serológicas son una herramienta valiosa para combatir la pandemia SARS-COV-2, pero no deben utilizarse como una herramienta única en el diagnóstico de infección viral dado el período de ventana inmunológica. El uso ideal de las pruebas se dará en los casos en que el paciente ya tenga más de 14 días de síntomas. La prueba One Step COVID-2019 de Guangzhou Wondfo Biotech reveló el mejor rendimiento entre los analizados.Introdução: Os testes imunológicos para a COVID-19 possuem como grande vantagem a sua rapidez diagnóstica, porém possuem taxa de eficácia variável a depender do fabricante, gerando a necessidade de identificar quais os melhores testes a serem utilizados a fim de evitar falsos diagnósticos. Objetivo: Apontar os testes disponíveis no Brasil que, dentro dos ensaios clínicos buscados, apresentam melhor taxa de eficácia. Métodos: Foram buscados na literatura artigos referentes a ensaios clínicos que testam a eficácia dos testes rápidos para a detecção de imunoglobulinas anti-SARS-COV-2. Para tal fim foi realizada uma busca sistemática nas bases de dados SCIELO, LILACS, PUBMED e MEDLINE utilizando os descritores SARS-COV-2, ELISA, COVID-19 e Avaliação, associados utilizando o operador booleano AND, logo em seguida foram aplicados critérios de inclusão e exclusão para selecionar os trabalhos a serem incluídos na revisão. Resultados: Foram incluídos 16 artigos que testaram 18 dos testes rápidos disponíveis no país. Conclusão: Os testes sorológicos são uma ferramenta de grande valia ao enfrentamento da pandemia do SARS-COV-2, porém não devem ser utilizados como ferramenta única no diagnóstico da infecção viral dado o período de janela imunológica. O emprego ideal dos testes dar-se-á nos casos em que o paciente já apresenta mais de 14 dias de sintomas. O teste One Step COVID-2019 da empresa Guangzhou Wondfo Biotech revelou o melhor desempenho dentre os analisados.Research, Society and Development2021-08-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1961510.33448/rsd-v10i11.19615Research, Society and Development; Vol. 10 No. 11; e264101119615Research, Society and Development; Vol. 10 Núm. 11; e264101119615Research, Society and Development; v. 10 n. 11; e2641011196152525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/19615/17506Copyright (c) 2021 Lucas Antonio de Oliveira Santos; Yuri Dias Macedo Campelo; Renata Paula Lima Beltrão; Gabriela de Souza Mendonça; Viviane Alves da Silva; Vanessa Meneses de Brito Campelohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSantos, Lucas Antonio de OliveiraCampelo, Yuri Dias MacedoBeltrão, Renata Paula LimaMendonça, Gabriela de Souza Silva, Viviane Alves daCampelo, Vanessa Meneses de Brito2021-10-23T19:01:11Zoai:ojs.pkp.sfu.ca:article/19615Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:39:29.047195Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
| dc.title.none.fl_str_mv |
Analysis of the effectiveness rate of rapid serological tests for COVID-19 registered in ANVISA, a systematic review in the literature Análisis de la tasa de efectividad de las pruebas serológicas rápidas para COVID-19 registradas en ANVISA, una revisión sistemática de la literatura Análise da taxa de eficácia dos testes sorológicos rápidos para COVID-19 registrados na ANVISA, uma revisão sistemática na literatura |
| title |
Analysis of the effectiveness rate of rapid serological tests for COVID-19 registered in ANVISA, a systematic review in the literature |
| spellingShingle |
Analysis of the effectiveness rate of rapid serological tests for COVID-19 registered in ANVISA, a systematic review in the literature Santos, Lucas Antonio de Oliveira SARS-COV-2 ELISA COVID-19 Avaliação. SARS-COV-2 ELISA COVID-19 Evaluación. SARS-COV-2 ELISA COVID-19 Evaluation. |
| title_short |
Analysis of the effectiveness rate of rapid serological tests for COVID-19 registered in ANVISA, a systematic review in the literature |
| title_full |
Analysis of the effectiveness rate of rapid serological tests for COVID-19 registered in ANVISA, a systematic review in the literature |
| title_fullStr |
Analysis of the effectiveness rate of rapid serological tests for COVID-19 registered in ANVISA, a systematic review in the literature |
| title_full_unstemmed |
Analysis of the effectiveness rate of rapid serological tests for COVID-19 registered in ANVISA, a systematic review in the literature |
| title_sort |
Analysis of the effectiveness rate of rapid serological tests for COVID-19 registered in ANVISA, a systematic review in the literature |
| author |
Santos, Lucas Antonio de Oliveira |
| author_facet |
Santos, Lucas Antonio de Oliveira Campelo, Yuri Dias Macedo Beltrão, Renata Paula Lima Mendonça, Gabriela de Souza Silva, Viviane Alves da Campelo, Vanessa Meneses de Brito |
| author_role |
author |
| author2 |
Campelo, Yuri Dias Macedo Beltrão, Renata Paula Lima Mendonça, Gabriela de Souza Silva, Viviane Alves da Campelo, Vanessa Meneses de Brito |
| author2_role |
author author author author author |
| dc.contributor.author.fl_str_mv |
Santos, Lucas Antonio de Oliveira Campelo, Yuri Dias Macedo Beltrão, Renata Paula Lima Mendonça, Gabriela de Souza Silva, Viviane Alves da Campelo, Vanessa Meneses de Brito |
| dc.subject.por.fl_str_mv |
SARS-COV-2 ELISA COVID-19 Avaliação. SARS-COV-2 ELISA COVID-19 Evaluación. SARS-COV-2 ELISA COVID-19 Evaluation. |
| topic |
SARS-COV-2 ELISA COVID-19 Avaliação. SARS-COV-2 ELISA COVID-19 Evaluación. SARS-COV-2 ELISA COVID-19 Evaluation. |
| description |
Introduction: The immunological tests for COVID-19 have the great advantage of their diagnostic speed, but their efficiency rate varies depending on the manufacturer, generating the need to identify the best tests to be used in order to avoid false diagnoses. Objective: To point out the tests available in Brazil, which within the clinical trials sought, have a better rate of effectiveness. Methods: Articles referring to clinical trials that test the effectiveness of rapid tests for the detection of anti-SARS-COV-2 immunoglobulins were searched in the literature. For this purpose, a systematic search was carried out in the SCIELO, LILACS, PUBMED and MEDLINE databases using the descriptors SARS-COV-2, ELISA, COVID-19 and Assessment in association using the Boolean operator AND, followed by the application of criteria for inclusion and exclusion to select the papers to be included in the review. Results: 16 articles that tested 18 of the rapid tests available in the country were included. Conclusion: serological tests are a valuable tool to fight the SARS-COV-2 pandemic, but should not be used as a single tool in the diagnosis of viral infection given the period of immunological window. The ideal use of the tests will occur in cases where the patient already has more than 14 days of symptoms. The One Step COVID-2019 test from Guangzhou Wondfo Biotech revealed the best performance among those analyzed. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021-08-31 |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/19615 10.33448/rsd-v10i11.19615 |
| url |
https://rsdjournal.org/index.php/rsd/article/view/19615 |
| identifier_str_mv |
10.33448/rsd-v10i11.19615 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/19615/17506 |
| dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Research, Society and Development |
| publisher.none.fl_str_mv |
Research, Society and Development |
| dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 11; e264101119615 Research, Society and Development; Vol. 10 Núm. 11; e264101119615 Research, Society and Development; v. 10 n. 11; e264101119615 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
| instname_str |
Universidade Federal de Itajubá (UNIFEI) |
| instacron_str |
UNIFEI |
| institution |
UNIFEI |
| reponame_str |
Research, Society and Development |
| collection |
Research, Society and Development |
| repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
| repository.mail.fl_str_mv |
rsd.articles@gmail.com |
| _version_ |
1797052825763577856 |